Current landscape for chimeric antigen receptor T cells in lymphomas.
CART cell therapy has changed the treatment landscape for relapsed/refractory aggressive lymphomas. In this article, we review the CART constructs most studied in lymphoma and their applicability. Results of ZUMA-1, JULIET and TRANSCEND trials will be reviewed. Real-world data will also be reviewed. CART cell therapy is evolving and becoming safer. Increased uptake of this modality outside of clinical trials is expected.